Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Prostaglandins Other Lipid Mediat. 2021 Mar 19;154:106548. doi: 10.1016/j.prostaglandins.2021.106548

Figure 3. Impact of 20-HETE cerebral VSMCs and pericytes contractile capability.

Figure 3.

A: Comparison of the contractile capability of primary VSMCs isolated from the MCA of SD rat treated with HET0016 in the absence or presence of WIT003. B: Comparison of the contractile capability of HBMVPs treated with HET0016 in the absence or presence of WIT003. The inserts are representative images and the white dotted circles represent the gel area after stimulation. Experiments were repeated 3–4 times in triplicates. * indicates P < 0.05 from the corresponding values in drugs-treated cells versus controls. VSMCs, vascular smooth muscle cells; MCA, middle cerebral artery; SD, Sprague Dawley; HET0016, N-Hydroxy-N′-(4-butyl-2-methylphenyl)-formamidine; WIT003, 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid; HBMVPs, human brain microvascular pericytes.